Extendicare (TSE:EXE) had its target price raised by stock analysts at National Bankshares from C$8.00 to C$8.50 in a note issued to investors on Monday, BayStreet.CA reports. National Bankshares’ price target would suggest a potential upside of 6.65% from the stock’s previous close.
Several other equities research analysts have also recently weighed in on EXE. National Bank Financial restated a “sector perform” rating and issued a C$7.00 price objective (up previously from C$6.50) on shares of Extendicare in a research report on Monday, March 1st. TD Securities raised their price target on shares of Extendicare from C$7.00 to C$8.00 and gave the company a “hold” rating in a report on Friday. Finally, Leede Jones Gab reaffirmed a “buy” rating on shares of Extendicare in a report on Monday, March 1st. Five analysts have rated the stock with a hold rating and one has issued a buy rating to the stock. The company has a consensus rating of “Hold” and a consensus target price of C$7.11.
EXE stock traded down C$0.12 during midday trading on Monday, reaching C$7.97. 130,891 shares of the company’s stock traded hands, compared to its average volume of 292,683. The company has a 50-day simple moving average of C$7.75 and a two-hundred day simple moving average of C$6.77. The company has a quick ratio of 0.93, a current ratio of 1.06 and a debt-to-equity ratio of 442.45. Extendicare has a 1-year low of C$5.06 and a 1-year high of C$8.13. The company has a market cap of C$713.81 million and a price-to-earnings ratio of 13.31.
Extendicare Company Profile
Extendicare Inc, through its subsidiaries, provides care and services for seniors in Canada. The company offers long term care (LTC) services; retirement living services; and home health care services, such as nursing care, occupational, physical and speech therapy, and assistance with daily activities, as well as contract and consulting services to third parties.
See Also: How does quantitative easing work?
Receive News & Ratings for Extendicare Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Extendicare and related companies with MarketBeat.com's FREE daily email newsletter.